Latest News for: ntla

Edit

Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc.(NTLA) of a Class Action Lawsuit and ...

Longview News-Journal 04 Apr 2025
NEW YORK, April 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ. NTLA) of a class action securities lawsuit ....
Edit

Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc.(NTLA) of a Class Action Lawsuit and an Upcoming Deadline

PR Newswire 04 Apr 2025
NTLA) of a class action securities lawsuit ... NTLA investors may also contact Joseph E ... As a result, defendants pipeline priority readjustment resulted in the Company's once-touted NTLA-3001's discontinuation.
Edit

NTLA Investors Have Opportunity to Lead Intellia Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Longview News-Journal 03 Apr 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Intellia To Contact Him Directly To Discuss Their Options ....
Edit

NTLA Deadline: NTLA Investors with Losses in Excess of $100K Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire 03 Apr 2025
NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2025 lead plaintiff deadline.
Edit

NTLA Investors are reminded of Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

PR Newswire 02 Apr 2025
NTLA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S ... The Company was not capable of providing patients with timely doses of NTLA-3001 or even to maintain full staffing.
Edit

Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) should contact Levi & Korsinsky about pending Class Action - NTLA

PR Newswire 01 Apr 2025
NTLA) of a class action securities lawsuit ... NTLA investors may also contact Joseph E ... As a result, defendants pipeline priority readjustment resulted in the Company's once-touted NTLA-3001's discontinuation.
Edit

INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Intellia Therapeutics, Inc. Investors ...

Nasdaq Globe Newswire 01 Apr 2025
INTELLIA THERAPEUTICS, INC. (NASDAQ. NTLA) DEADLINE ALERT. Bernstein Liebhard LLP Reminds Intellia Therapeutics, Inc. Investors of Upcoming Deadline ... .
Edit

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA

PR Newswire 31 Mar 2025
NEW YORK, March 31, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc ("Intellia" or the "Company") (NASDAQ .NTLA).  ...
Edit

Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NTLA

PR Newswire 28 Mar 2025
NTLA) of a class action securities lawsuit ... NTLA investors may also contact Joseph E ... study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease.
×